Unlock more results with a Fundz subscription — Get started today!

Get real-time alerts on funding rounds, executive hires, acquisitions, and more— plus verified contact details and AI-powered outreach to connect faster.
Sign up now to unlock exclusive data and opportunities.

Lumicks Raises $93 Million In Series D Financing

04/16/21, 9:40 AM

Location

amsterdam

Money raised

$93 million

Round Type

series d

LUMICKS, a leading, next-generation life science tools company that develops highly innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, announced the completion of a $93 million Series D preferred share financing.

Company Info

Company

Lumicks

Location

amsterdam, new york, united states

Additional Info

LUMICKS is a leading life science tools company that develops equipment for Dynamic Single-Molecule and Cell Avidity analysis, two rapidly emerging areas in biology research and immuno-oncology. Built upon innovative technologies, such as optical tweezers (Nobel Prize for Physics 2018) and STED super-resolution (Nobel Prize for Chemistry 2014), LUMICKS tools facilitate the understanding of life to the smallest detail.

Company news

Tue, 20 Aug 2024 07:00:00 GMT

Differential dynamics specify MeCP2 function at nucleosomes and methylated DNA - Nature.com

Thu, 28 Jun 2018 07:00:00 GMT

AstraZeneca launches Cambridge partnership with Lumicks to visualize individual DNA, drug molecules - Fierce Biotech

Wed, 14 Dec 2022 08:04:48 GMT

A direct view of DNA repair and beyond - Nature.com

Wed, 23 Nov 2022 08:00:00 GMT

Smc5/6’s multifaceted DNA binding capacities stabilize branched DNA structures - Nature.com

Sat, 09 Jul 2022 07:00:00 GMT

Chromatin sequesters pioneer transcription factor Sox2 from exerting force on DNA - Nature.com

Never Miss an Opportunity: Your #1 Sales Intelligence Tool

Get lightning-fast updates on funding rounds, executive hires, contract awards, and more—powered by AI-driven insights to help you connect with the right prospects first.